PTC Therapeutics Inc

Research PTC Therapeutics Inc (PTCT) on Bullrun: market cap USD 6.77B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPTCT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 6.77B
• Financial periodFY2025
• RevenueUSD 1.73B
• Revenue growth114.5%
• Net incomeUSD 683.00M
• Free cash flowUSD 702.34M

Valuation Snapshot

latest market cap is USD 6.77B.

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases;

Frequently asked questions

What is PTC Therapeutics Inc's market cap?

PTC Therapeutics Inc's market capitalization is USD 6.77B.

What does PTC Therapeutics Inc do?

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.